Pharmacologic evidence to support clinical decision making for peripartum methadone treatment

Psychopharmacology

Volumn 225, Issue 2, 2013, Pages 441-451

  Bogen, D L ^a   Perel, J M ^a,b   Helsel, J C ^a,b   Hanusa, B H ^a   Romkes, M ^b   Nukui, T ^b   Friedman, C R ^a   Wisner, K L ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

CYP2B6; CYP2C19; CYP3A4; Half life; Pharmacokinetics; Postpartum; Pregnancy; R Methadone; Rac methadone; S Methadone

Indexed keywords

CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 3A4; METHADONE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CAUCASIAN; CLINICAL ARTICLE; CLINICAL DECISION MAKING; CLINICAL TRIAL; CYTOCHROME P450 2B6 GENE; CYTOCHROME P450 2C19 GENE; CYTOCHROME P450 3A4 GENE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFECT; DRUG HALF LIFE; DRUG RETENTION; ENANTIOMER; FEMALE; GENE INTERACTION; GENETIC VARIABILITY; HUMAN; MEDICAID; METHADONE TREATMENT; OPIATE ADDICTION; PERINATAL PERIOD; PREGNANCY OUTCOME; PREGNANT WOMAN; PRIORITY JOURNAL; PUERPERIUM; SECOND TRIMESTER PREGNANCY; SINGLE NUCLEOTIDE POLYMORPHISM; STEADY STATE; THIRD TRIMESTER PREGNANCY; TREATMENT DURATION; WOMEN'S HEALTH;

ADOLESCENT; ADULT; ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 CYP3A; DECISION MAKING; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENOTYPE; HALF-LIFE; HUMANS; LONGITUDINAL STUDIES; METHADONE; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; OXIDOREDUCTASES, N-DEMETHYLATING; PERIPARTUM PERIOD; POLYMORPHISM, SINGLE NUCLEOTIDE; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY TRIMESTER, THIRD; PROSPECTIVE STUDIES; STEREOISOMERISM; YOUNG ADULT;

EID: 84872352603     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-012-2833-7     Document Type: Article

References (37)

1. Abdel-Latif ME, Pinner J et al (2006) Effects of breast milk on the severity and outcome of neonatal abstinence syndrome among infants of drug-dependent mothers. Pediatrics 117(6):e1163-1169
2. Anderson GD (2005) Pregnancy-induced changes in pharmacokinetics: a mechanistic-based approach. Clin Pharmacokinet 44:989-1008
3. Arlettaz R, Kashiwagi M et al (2005) Methadone maintenance program in pregnancy in a Swiss perinatal center (II): neonatal outcome and social resources. Acta Obstet Gynecol Scand 84(2):145-150
4. Ballard JL (2002) Treatment of neonatal abstinence syndrome with breast milk containing methadone. J Perinat Neonatal Nurs 15(4):76-85
5. Bogen D, Perel J et al (2011) Exposure to enantiomer-specific methadone levels in breastmilk. Breastfeed Med 6(6):377-384
6. Chang Y, Fang WB et al (2011) Stereo-selective metabolism of methadone by human liver microsomes and cDNA-expressed cytochrome P450s: a reconciliation. Basic Clin Pharmacol Toxicol 108(1):55-62
7. Crettol S, Déglon J-J et al (2005) Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment. Clin Pharmacol Ther 78:593-604
8. Eap CB, Cuendet C et al (1990) Binding of d-methadone, l-methadone, and dl-methadone to proteins in plasma of healthy volunteers: role of the variants of alpha 1-acid glycoprotein. Clin Pharmacol Ther 47(3):338-346
9. Eap CB, Bertschy G et al (1998) High interindividual variability of methadone enantiomer blood levels to dose ratios. Arch Gen Psychiatry 55(1):89-90
10. Eap CB, Buclin T et al (2002) Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. Clin Pharmacokinet 41(14):1153-1193
11. Elkader AK, Brands B et al (2009) Methadone-nicotine interactions in methadone maintenance treatment patients. J Clin Psychopharmacol 29(3):231-238. doi: 10.1097/JCP.0b013e3181a39113
12. Foster D, Somogyi A et al (2000) Steady-state pharmacokinetics of (R)- and (S)-methadone in methadone maintenance patients. Br J Clin Pharmacol 50(5):427-440
13. Foster DJ, Somogyi AA et al (2004) Population pharmacokinetics of (R)-, (S)- and rac-methadone in methadone maintenance patients. Br J Clin Pharmacol 57(6):742-755
14. Frederiksen M (2001) Physiologic changes in pregnancy and their effect on drug disposition. Semin Perinatol 25(3):120-123
15. Gerber JG, Rhodes RJ et al (2004) Stereoselective metabolism of methadone N-demethylation by cytochrome P4502B6 and 2C19. Chirality 16(1):36-44
16. Hallinan R, Crettol S et al (2009) Cannabis and benzodiazepines as determinants of methadone trough plasma concentration variability in maintenance treatment: a transnational study. Eur J Clin Pharmacol 65(11):1113-1120
17. Hirschfeld RMA et al (2000) Development and validation of a screening instrument for bipolar spectrum disorder: the mood disorder questionnaire. Am J Psychiatry 157(11):1873-1875
18. Hirt D, Treluyer J et al (2006) Pregnancy-related effects on nelfinavir-M8 pharmacokinetics: a population study with 133 women. Antimicrob Agents Chemother 50(6):2079-2086
19. Jansson LM, Choo R et al (2008) Methadone maintenance and long-term lactation. Breastfeed Med 3(1):34-37
20. Jansson LM, Dipietro JA et al (2009) Maternal methadone dosing schedule and fetal neurobehaviour. J Matern Fetal Neonatal Med 22(1):29-35
21. Jones H, Johnson R et al (2008) Dosing adjustments in postpartum patients maintained on buprenorphine or methadone. J Addict Med 2(2):103-107
22. Kharasch E, Hoffer C et al (2004) Role of hepatic and intestinal cytochrome P450 3A and 2B in the metabolism, disposition and miotic effects of methadone. Clin Parmacol Ther 76:250-269
23. Kharasch ED, Hoffer C et al (2009) Methadone pharmacokinetics are independent of cytochrome P4503A (CYP3A) activity and gastrointestinal drug transport. Anesthesiology 110:660-672
24. Kristensen K, Christensen CB et al (1995) The mu1, mu2, delta, kappa opioid receptor binding profiles of methadone stereoisomers and morphine. Life Sci 56(2):PL45-50
25. Kristensen K, Blemmer T et al (1996) Stereoselective pharmacokinetics of methadone in chronic pain patients. Ther Drug Monit 18(3):221-227
26. NIH Consensus Statement (1997) Effective medical treatment of opiate addiction. 15(6):1-38
27. Pond SM, Kreek MJ et al (1985) Altered methadone pharmacokinetics in methadone-maintained pregnant women. J Pharmacol Exp Ther 233(1):1-6
28. Prins A et al (2003) The primary care PTSD screen (PC-PTSD): development and operating characteristics. Primary Care Psychiatry 9:9-14
29. Robson S, Mutch E et al (1990) Apparent liver blood flow during pregnancy: a serial study using indocyanine green clearance. Br J Obstet Gynaecol 97:720-724
30. The Academy of Breastfeeding Medicine Protocol Committee, Jansson LM (2009) ABM clinical protocol #21: guidelines for breastfeeding and the drug-dependent woman. Breastfeed Med 4(4):225-228
31. Tolson AH, Li H et al (2009) Methadone induces the expression of hepatic drug-metabolizing enzymes through the activation of pregnane x receptor and constitutive androstane receptor. Drug Metab Dispos 37(9):1887-1894
32. Tomedi L, Bogen D et al (2012) A pilot study of the nutritional status of opiate abusing pregnant women on methadone maintenance therapy. Subst Use Misuse 47(3):286-295
33. Totah RA, Sheffels P et al (2008) Role of CYP2B6 in stereoselective human methadone metabolism. Anesthesiology 108:363-374
34. Tracy TS, Venkataramanan R et al (2005) Temporal changes in drug metabolism (CYP1A2, CYP2D6 and CYP3A activity) during pregnancy. Am J Obstet Gynecol 192(2):633-639
35. van Heeswijk R, Khaliq Y et al (2004) The pharmacokinetics of nelfinavir and M8 during pregnancy and postpartum. Clin Pharmacol Ther 766:588-597
36. Wesson D, Ling W (2003) The Clinical Opiate Withdrawal Scale (COWS). J Psychoactive Drugs 35(2):253-259
37. Wisner KL, Perel JM et al (1997) Effects of the postpartum period on nortriptyline pharmacokinetics. Psychopharmacol Bull 33(2):243-248